Dr. Andy Y. Lee, MD
Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)
- Medicare participating
At a glance
- Years since graduation
- 7
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 1,656
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Advanced Heart Failure and Transplant Cardiology Physician primary
CA license A135643 -
Cardiovascular Disease Physician
CA license A135643 -
Internal Medicine Physician
CA license A135643
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Heart Failure & Transplant Cardiology per capita by county →
Where they work
Hospitals
- Uci Health-Orange Orange, CA
- Hoag Memorial Hospital Presbyterian Newport Beach, CA
Medical groups
- Hoag Clinic (460 clinicians)
- UC Regents (319 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,656
- Services billed
- 2,825
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 716 | 624 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 321 | 318 |
| Established patient office or other outpatient visit, 30-39 minutes | 255 | 157 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 107 | 107 |
| Established patient office or other outpatient visit, 20-29 minutes | 97 | 75 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 92 | 91 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 90 | 30 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 67 | 67 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 63 | 63 |
| Ultrasound of heart blood flow, valves and chambers | 56 | 56 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Atorvastatin Calcium Other prescribers in Newport Beach, CA | 200 |
| Metoprolol Succinate Other prescribers in Newport Beach, CA | 189 |
| Spironolactone Other prescribers in Newport Beach, CA | 178 |
| Losartan Potassium Other prescribers in Newport Beach, CA | 151 |
| Eliquis (apixaban) Other prescribers in Newport Beach, CA | 149 |
| Entresto (sacubitril/valsartan) Other prescribers in Newport Beach, CA | 141 |
| Jardiance (empagliflozin) Other prescribers in Newport Beach, CA | 122 |
| Carvedilol Other prescribers in Newport Beach, CA | 122 |
| Furosemide Other prescribers in Newport Beach, CA | 103 |
| Amlodipine Besylate Other prescribers in Newport Beach, CA | 79 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 13 payments worth $1,445 in total to this clinician.
| Abbott Laboratories | $877 |
|---|---|
| Novartis Pharmaceuticals Corporation | $247 |
| Abiomed | $189 |
| Ancora Heart, Inc. | $71.77 |
| Regeneron Healthcare Solutions, Inc. | $32.97 |
| E.r. Squibb & Sons, L.l.c. | $27.93 |
| Food and Beverage | $749 |
|---|---|
| Travel and Lodging | $696 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Abbott Laboratories Nov 26, 2025 | Travel and Lodging CARDIOMEMS · Structural Heart · travel to San Francisco, CA · in-kind | $597 |
| Abbott Laboratories Nov 26, 2025 | Travel and Lodging CARDIOMEMS · Structural Heart · travel to San Francisco, CA · in-kind | $90.06 |
| Abbott Laboratories Nov 26, 2025 | Travel and Lodging CARDIOMEMS · Structural Heart · travel to San Francisco, CA · in-kind | $9.02 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $90,389 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly…
Amgen Inc. - A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company · Active, not recruiting · NCT05556512 - A multi-center, randomized, double-blind placebo-controlled and open-label active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.